These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18765824)

  • 1. Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides.
    de Wolf C; Jansen R; Yamaguchi H; de Haas M; van de Wetering K; Wijnholds J; Beijnen J; Borst P
    Mol Cancer Ther; 2008 Sep; 7(9):3092-102. PubMed ID: 18765824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deoxycytidine kinase modulates the impact of the ABC transporter ABCG2 on clofarabine cytotoxicity.
    Nagai S; Takenaka K; Nachagari D; Rose C; Domoney K; Sun D; Sparreboom A; Schuetz JD
    Cancer Res; 2011 Mar; 71(5):1781-91. PubMed ID: 21245102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABC transporters and their role in nucleoside and nucleotide drug resistance.
    Fukuda Y; Schuetz JD
    Biochem Pharmacol; 2012 Apr; 83(8):1073-83. PubMed ID: 22285911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.
    Kim M; Turnquist H; Jackson J; Sgagias M; Yan Y; Gong M; Dean M; Sharp JG; Cowan K
    Clin Cancer Res; 2002 Jan; 8(1):22-8. PubMed ID: 11801536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists.
    To KK; Tomlinson B
    Br J Pharmacol; 2013 Nov; 170(5):1137-51. PubMed ID: 24032744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors.
    Jensen K; Johnson LA; Jacobson PA; Kachler S; Kirstein MN; Lamba J; Klotz KN
    Naunyn Schmiedebergs Arch Pharmacol; 2012 May; 385(5):519-25. PubMed ID: 22249336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the role of nucleoside transporters, P-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in the placental transport of entecavir using in vitro, ex vivo, and in situ methods.
    Cerveny L; Karbanova S; Karahoda R; Horackova H; Jiraskova L; Ali MNH; Staud F
    Toxicol Appl Pharmacol; 2023 Mar; 463():116427. PubMed ID: 36801311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance.
    Ifergan I; Scheffer GL; Assaraf YG
    Cancer Res; 2005 Dec; 65(23):10952-8. PubMed ID: 16322243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.
    Marchetti S; Oostendorp RL; Pluim D; van Eijndhoven M; van Tellingen O; Schinkel AH; Versace R; Beijnen JH; Mazzanti R; Schellens JH
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3307-13. PubMed ID: 18089724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming multidrug resistance via photodestruction of ABCG2-rich extracellular vesicles sequestering photosensitive chemotherapeutics.
    Goler-Baron V; Assaraf YG
    PLoS One; 2012; 7(4):e35487. PubMed ID: 22530032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems.
    King KM; Damaraju VL; Vickers MF; Yao SY; Lang T; Tackaberry TE; Mowles DA; Ng AM; Young JD; Cass CE
    Mol Pharmacol; 2006 Jan; 69(1):346-53. PubMed ID: 16234483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABCG2 modulates chlorothiazide permeability--in vitro-characterization of its interactions.
    Beéry E; Rajnai Z; Abonyi T; Makai I; Bánsághi S; Erdő F; Sziráki I; Herédi-Szabó K; Kis E; Jani M; Márki-Zay J; Tóth GK; Krajcsi P
    Drug Metab Pharmacokinet; 2012; 27(3):349-53. PubMed ID: 22790065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
    Bram EE; Ifergan I; Grimberg M; Lemke K; Skladanowski A; Assaraf YG
    Biochem Pharmacol; 2007 Jun; 74(1):41-53. PubMed ID: 17481587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
    Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
    Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
    Han B; Zhang JT
    Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):31-42. PubMed ID: 14754410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.